News

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...
New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...
A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...
A doctor at Monday’s event said some of the reasons for Iowa’s increased cancer rate include HPV, alcohol use, and the state’s higher obesity rate.
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...
In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...
With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...
The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...
Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings ...
Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...